PMID- 17645555
OWN - NLM
STAT- MEDLINE
DCOM- 20090220
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 10
IP  - 8
DP  - 2008 Aug
TI  - Association between oral antidiabetic use, adverse events and outcomes in 
      patients with type 2 diabetes.
PG  - 638-45
AB  - OBJECTIVE: To quantify adverse events (AEs) associated with the use of metformin 
      (MET), sulphonylureas (SUs) and thiazolidinediones (TZDs) in a usual care 
      setting, and to assess the relationship of AEs to treatment patterns and 
      glycaemic response in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: 
      An electronic medical record database was used to identify patients with type 2 
      diabetes age >or=18 years from 1996 to 2005. Patients naive to oral antidiabetic 
      therapy were followed for 395 days postinitiation of MET, SU or TZD treatment. 
      AEs related to study drugs were evaluated during the follow-up period. Baseline 
      and follow-up A1C levels were compared by drug regimen. Associations between the 
      change in A1C, drug regimen changes and AEs were evaluated. RESULTS: A total of 
      14,512 patients (mean age 60.8 years, 52.9% female) were identified. During the 
      follow-up period, 12.7% of patients experienced an AE (8.6% MET, 15.9% SU and 
      19.8% TZD patients). SU and TZD patients were more likely to experience an AE 
      than MET (p < 0.001) patients. AEs did not significantly influence A1C outcomes, 
      although MET and SU patients experiencing an AE were more likely to add-on 
      therapy (odds ratio (OR) = 1.34 and OR = 1.37, respectively; p < 0.05) than those 
      without an AE. MET patients with AEs were more likely to switch therapy (OR = 
      1.91; p < 0.05) than those without an AE. CONCLUSIONS: The occurrence of AEs did 
      not significantly impact glycaemic response to therapy. However, AEs may lead to 
      greater treatment switches for patients receiving MET and add-on therapy for 
      MET-treated and SU-treated patients.
FAU - Asche, C V
AU  - Asche CV
AD  - Outcomes Research Center, Department of Pharmacotherapy, University of Utah 
      College of Pharmacy, Salt Lake City, UT 84108, USA. carl.asche@pharm.utah.edu
FAU - McAdam-Marx, C
AU  - McAdam-Marx C
FAU - Shane-McWhorter, L
AU  - Shane-McWhorter L
FAU - Sheng, X
AU  - Sheng X
FAU - Plauschinat, C A
AU  - Plauschinat CA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070721
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/drug effects/*metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Male
MH  - Metformin/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Sulfonylurea Compounds/*administration & dosage/adverse effects
MH  - Thiazolidinediones/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2007/07/25 09:00
MHDA- 2009/02/21 09:00
CRDT- 2007/07/25 09:00
PHST- 2007/07/25 09:00 [pubmed]
PHST- 2009/02/21 09:00 [medline]
PHST- 2007/07/25 09:00 [entrez]
AID - DOM758 [pii]
AID - 10.1111/j.1463-1326.2007.00758.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2008 Aug;10(8):638-45. doi: 
      10.1111/j.1463-1326.2007.00758.x. Epub 2007 Jul 21.